Delineate
delineate.proDelineate uses AI to turn biopharma literature and patent evidence into quantitative insights for development decisions.
- Specialization
Language Modelsand 1 more specialization valuesLess
- Computer Vision
- Business
Data Provisionand 1 more business valuesLess
- Professional Services
- Market
- Life Sciences
- Ecosystem
- AI for science
- Customers
- Enterprises
More details
- Organization type
- Commercial Company
- Ecosystem
- AI for science
- Business
- Data Provision, Professional Services
- Specialization
- Language Models, Computer Vision
- Market
- Life Sciences
- Customers
- Enterprises
- Delivery models
- Professional Services
- Revenue models
- Services Fees
- Listing status
- Not classified
- Latest equity round
- Seed
- Reported funding amount
- Not classified
About
Delineate builds AI-powered evidence-aggregation and decision-support software for biopharma and pharmaceutical companies. Its system extracts and analyzes information from research papers and patents—including figures and plots—using custom large language models, computer vision, and rigorous quality-control processes to produce high-quality datasets faster than conventional research workflows.
Market
Delineate competes in AI-enabled biopharma R&D intelligence, evidence synthesis, and clinical-development decision support. Its positioning centers on converting unstructured papers, patents, figures, and plots into high-quality, quantitative, analysis-ready datasets, then applying agentic analysis to consequential development decisions. Compared with Causaly’s broad enterprise knowledge graph, DistillerSR’s literature-review workflow, Scite’s citation-evaluation platform, and PhaseV/Atropos Health’s clinical-trial or real-world-evidence products, Delineate’s clearest differentiation is bespoke multimodal evidence construction for pharma-specific workflows.
Large pharmaceutical and biopharmaceutical companies—particularly enterprise-scale or top-tier pharma organizations—with research, clinical-development, evidence-generation, pharmacometrics, or competitive-intelligence teams. Likely buyers are R&D and clinical-development leaders who need quantitative evidence to support trial design, drug-development, and go/no-go decisions.
At a Glance
Problem
Delineate addresses the slow, fragmented and increasingly outdated nature of conventional brand and campaign tracking. Annual or infrequent studies do not give marketers enough granularity or timeliness to understand what consumers think in the moment, compare national and local markets, or adjust campaigns while they are still running. The economic pain is wasted media spend, delayed learning and weaker campaign effectiveness; Coca-Cola’s case describes a lack of consistent global measurement and agility, while its client reports at least a 25% improvement in campaign effectiveness after gaining the ability to shape campaigns on the fly.
The clearest use case is global, continuous campaign and advertising-experience measurement for major brands. Instead of waiting for post-campaign analysis, brand, media and insight teams can see live consumer feedback, identify what is working across markets, and optimise investment in-flight.
Product / Service
Delineate provides an always-on market-research and brand-tracking service built around its proprietary Delineate Proximity® platform. The platform connects brands with consumers through ongoing surveys, uses automated or AI-enabled sampling and survey deployment, and turns the resulting data into continuously updated insight dashboards. It can collect brand-health and campaign-performance data simultaneously, at national, city or other market levels, with daily data and robust weekly samples for analysis.
The delivery model combines global standardisation with operational flexibility: clients receive live or daily data, can add markets or ad-hoc tracking quickly, and can access results through a dashboard rather than waiting for a periodic report. Automation lowers production costs—Cint reports that AI has nearly eliminated Delineate’s production-labour costs—while giving clients faster feedback and the ability to compare markets, learn across campaigns and improve decisions in real time.
Market
Delineate competes in market research, particularly real-time brand tracking, campaign evaluation, advertising and communications measurement, audience intelligence and consumer-opinion research. The evidence does not identify named direct competitors; strategically, the company differentiates itself from traditional annual tracking approaches and less-agile research delivery partners. Cint is a key technology and sample-supply partner rather than a direct competitor, providing panel access and automated respondent validation.
The company is clearly beyond a pre-revenue proof of concept, although revenue figures are not disclosed in the available evidence. Delineate was founded in 2017 and is listed with 47 employees; its customer traction includes Coca-Cola, for which it has tracked thousands of campaigns since 2022 across 40 always-on markets and as many as 55 markets in a year, as well as Salomon’s daily national and city-level brand and campaign tracking programme. These deployments indicate an enterprise-focused business with meaningful multinational usage and repeat operational scale.
Founders & Leadership
Funding History
Y Combinator, Unpopular Ventures
Recent News
Delineate announced its participation in BIO 2026 and invited meetings with teams interested in fit-for-purpose databases built from clinical literature, patents, and conference proceedings. The company highlighted quantitative support for biopharma development decisions.
Delineate promoted a Rosa & Co. LLC webinar focused on using generative AI to reduce Model-Based Meta-Analysis timelines, highlighting the company’s work in AI-enabled biopharma analytics.
Active Roles
0No active roles right now.
Get notified when they postBusiness Model
Delineate makes money by providing bespoke AI services and evidence-aggregation projects for biopharma and pharmaceutical companies, delivering fit-for-purpose datasets and analysis workflows. Public materials do not disclose standard pricing, subscription tiers, or specific revenue terms.